Escitalopram: a review of its use in the management of anxiety disorders (Q36585863)

15 August 2017

1 reference

title

Escitalopram: a review of its use in the management of anxiety disorders (English)

1 reference

15 August 2017

1 reference

ChEBI release 2020-05-28

3

Greg L Plosker

1 reference

15 August 2017

2

Lesley J Scott

1 reference

15 August 2017

1

Sohita Dhillon

1 reference

15 August 2017

publication date

1 January 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

20

1 reference

15 August 2017

issue

9

1 reference

15 August 2017

page(s)

763-790

1 reference

The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects

15 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165/00023210-200620090-00010

Prevalence, Severity, and Unmet Need for Treatment of Mental Disorders in the World Health Organization World Mental Health Surveys

21 January 2018

1 reference

12 December 2020

SSRIs as mood stabilizers for Bipolar II Disorder? A proof of concept study

1 reference

12 December 2020

An open trial of adjunctive escitalopram in bipolar depression.

1 reference

12 December 2020

Comorbidity of anxiety and depressive disorders: issues in conceptualization, assessment, and treatment

1 reference

12 December 2020

Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study

1 reference

12 December 2020

Escitalopram: a review of its use in the management of major depressive disorder.

1 reference

12 December 2020

Escitalopram, the S-( )-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities

1 reference

12 December 2020

Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study

1 reference

12 December 2020

Early life trauma decreases glucocorticoid receptors in rat dentate gyrus upon adult re-stress: reversal by escitalopram

1 reference

12 December 2020

Anxiolytic-Like Effects of Escitalopram, Citalopram, and R-Citalopram in Maternally Separated Mouse Pups

1 reference

12 December 2020

Identifying and treating panic disorder in primary care.

1 reference

12 December 2020

Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review

1 reference

12 December 2020

Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study

1 reference

12 December 2020

Studies on the Stereoselective Metabolism of Citalopram by Human Liver Microsomes and cDNA-Expressed Cytochrome P450 Enzymes

1 reference

12 December 2020

Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials

1 reference

12 December 2020

A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder

1 reference

12 December 2020

Citalopram and demethylcitalopram in human milk; distribution, excretion and effects in breast fed infants.

1 reference

12 December 2020

ECNP Consensus Meeting, March 2003. Guidelines for the investigation of efficacy in social anxiety disorder

1 reference

12 December 2020

R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model.

1 reference

12 December 2020

The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects

1 reference

12 December 2020

The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors

1 reference

12 December 2020

A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder.

1 reference

12 December 2020

Escitalopram versus citalopram: the surprising role of the R-enantiomer

1 reference

12 December 2020

An open-label study of escitalopram in body dysmorphic disorder

1 reference

12 December 2020

The pharmacokinetics of escitalopram in patients with hepatic impairment

1 reference

12 December 2020

Hippocampal cytogenesis correlates to escitalopram-mediated recovery in a chronic mild stress rat model of depression

1 reference

12 December 2020

New possibilities of treatment for panic attacks in elderly patients: escitalopram versus citalopram.

1 reference

12 December 2020

Regional pattern of binding and c-Fos induction by (R)- and (S)-citalopram in rat brain

1 reference

12 December 2020

Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain

1 reference

12 December 2020

Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder

1 reference

12 December 2020

Allosteric modulation of the effects of the 5-HT reuptake inhibitor escitalopram on the rat hippocampal synaptic plasticity

1 reference

12 December 2020

Escitalopram for social anxiety disorder

1 reference

12 December 2020

R-citalopram counteracts the effect of escitalopram in a rat conditioned fear stress model of anxiety

1 reference

12 December 2020

Escitalopram versus paroxetine for social anxiety disorder: an analysis of efficacy for different symptom dimensions

1 reference

12 December 2020

Escitalopram : a review of its use in the management of major depressive and anxiety disorders

1 reference

12 December 2020

Escitalopram and suicidality in adult depression and anxiety

1 reference

12 December 2020

Managing depressive and anxiety disorders with escitalopram

1 reference

12 December 2020

Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine

1 reference

12 December 2020

A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.

1 reference

12 December 2020

Escitalopram versus venlafaxine XR in the treatment of depression

1 reference

12 December 2020

A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder

1 reference

12 December 2020

Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial.

1 reference

12 December 2020

Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study

1 reference

12 December 2020

Outcomes after supratherapeutic escitalopram ingestions

1 reference

12 December 2020

Effects of chronic treatment with escitalopram or citalopram on extracellular 5-HT in the prefrontal cortex of rats: role of 5-HT1A receptors

1 reference

12 December 2020

R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram

1 reference

12 December 2020

Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram

1 reference

12 December 2020

A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.

1 reference

12 December 2020

Differences in total medical costs across the SSRIs for the treatment of depression and anxiety

1 reference

12 December 2020

R-citalopram attenuates anxiolytic effects of escitalopram in a rat ultrasonic vocalisation model

1 reference

12 December 2020

The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats

1 reference

12 December 2020

An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir

1 reference

12 December 2020

Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial.

1 reference

12 December 2020

Escitalopram in the treatment of generalized anxiety disorder

1 reference

12 December 2020

Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes

1 reference

12 December 2020

A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression

1 reference

12 December 2020

Comparison of the effects of citalopram and escitalopram on 5-Ht-mediated neuroendocrine responses

1 reference

12 December 2020

Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology

1 reference

12 December 2020

Transfer of escitalopram and its metabolite demethylescitalopram into breastmilk

1 reference

12 December 2020

Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies

1 reference

12 December 2020

R-citalopram functionally antagonises escitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter

1 reference

12 December 2020

Improved potency of escitalopram on the human serotonin transporter: demonstration of an ex vivo assay technique

1 reference

12 December 2020

10.2165/00023210-200620090-00010

Identifiers

DOI

1 reference

Dimensions Publication ID

15 August 2017

1015159648

0 references

1 reference